A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy

Autores
Piñeiro, Federico Jesús; Fernández Argüelles, Rogelio Alberto
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction/Objective: To describe the chiral switch, an evergreening strategy used by AstraZeneca to position enantiopure esomeprazole as the new proton pump inhibitor market leader, displacing its predecessor omeprazole.Methodology: A four-stage systematic review which included: a preliminary review, bibliographic review using databases, classification of the body of literature, and content analysis.Results: Using different legal and commercial strategies, such as patent thickets and aggressive publicity campaigns, AstraZeneca transferred consumer loyalty from their successful omeprazole to esomeprazole, its new and more expensive patent protected product which has the same therapeutic value as its predecessor. This chiral switch allowed AstraZeneca to maintain monopoly prices, which increased the financial burden experienced by consumers and payors and may have also had a negative impact on access to the medication.Conclusions: This case study exemplifies how the current patent system, including patent thickets, can be used to enhance the profits of pharmaceutical companies while stalling innovation and placing undue financial burdens on the consumer.
Fil: Piñeiro, Federico Jesús. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Lanús. Rectorado. Instituto de Salud Colectiva; Argentina
Fil: Fernández Argüelles, Rogelio Alberto. Universidad Autónoma de Nayarit; México
Materia
ASTRAZENECA
BIG PHARMA
CHIRAL SWITCH
GENERICS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/200816
Acceder
id CONICETDig_5190855a4dab5d030c2bc0a910b91022
oai_identifier_str oai:ri.conicet.gov.ar:11336/200816
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategyPiñeiro, Federico JesúsFernández Argüelles, Rogelio AlbertoASTRAZENECABIG PHARMACHIRAL SWITCHGENERICShttps://purl.org/becyt/ford/3.5https://purl.org/becyt/ford/3Introduction/Objective: To describe the chiral switch, an evergreening strategy used by AstraZeneca to position enantiopure esomeprazole as the new proton pump inhibitor market leader, displacing its predecessor omeprazole.Methodology: A four-stage systematic review which included: a preliminary review, bibliographic review using databases, classification of the body of literature, and content analysis.Results: Using different legal and commercial strategies, such as patent thickets and aggressive publicity campaigns, AstraZeneca transferred consumer loyalty from their successful omeprazole to esomeprazole, its new and more expensive patent protected product which has the same therapeutic value as its predecessor. This chiral switch allowed AstraZeneca to maintain monopoly prices, which increased the financial burden experienced by consumers and payors and may have also had a negative impact on access to the medication.Conclusions: This case study exemplifies how the current patent system, including patent thickets, can be used to enhance the profits of pharmaceutical companies while stalling innovation and placing undue financial burdens on the consumer.Fil: Piñeiro, Federico Jesús. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Lanús. Rectorado. Instituto de Salud Colectiva; ArgentinaFil: Fernández Argüelles, Rogelio Alberto. Universidad Autónoma de Nayarit; MéxicoPro Pharma Communications International2022-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/200816Piñeiro, Federico Jesús; Fernández Argüelles, Rogelio Alberto; A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy; Pro Pharma Communications International; Generics and Biosimilars Initiative Journal; 11; 2; 5-2022; 57-642033-64032033-6772CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://gabi-journal.net/a-case-study-of-astrazenecas-omeprazole-esomeprazole-chiral-switch-strategy.htmlinfo:eu-repo/semantics/altIdentifier/doi/10.5639/gabij.2022.1102.011info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:39:07Zoai:ri.conicet.gov.ar:11336/200816instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:39:07.927CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
title A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
spellingShingle A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
Piñeiro, Federico Jesús
ASTRAZENECA
BIG PHARMA
CHIRAL SWITCH
GENERICS
title_short A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
title_full A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
title_fullStr A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
title_full_unstemmed A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
title_sort A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
dc.creator.none.fl_str_mv Piñeiro, Federico Jesús
Fernández Argüelles, Rogelio Alberto
author Piñeiro, Federico Jesús
author_facet Piñeiro, Federico Jesús
Fernández Argüelles, Rogelio Alberto
author_role author
author2 Fernández Argüelles, Rogelio Alberto
author2_role author
dc.subject.none.fl_str_mv ASTRAZENECA
BIG PHARMA
CHIRAL SWITCH
GENERICS
topic ASTRAZENECA
BIG PHARMA
CHIRAL SWITCH
GENERICS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.5
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction/Objective: To describe the chiral switch, an evergreening strategy used by AstraZeneca to position enantiopure esomeprazole as the new proton pump inhibitor market leader, displacing its predecessor omeprazole.Methodology: A four-stage systematic review which included: a preliminary review, bibliographic review using databases, classification of the body of literature, and content analysis.Results: Using different legal and commercial strategies, such as patent thickets and aggressive publicity campaigns, AstraZeneca transferred consumer loyalty from their successful omeprazole to esomeprazole, its new and more expensive patent protected product which has the same therapeutic value as its predecessor. This chiral switch allowed AstraZeneca to maintain monopoly prices, which increased the financial burden experienced by consumers and payors and may have also had a negative impact on access to the medication.Conclusions: This case study exemplifies how the current patent system, including patent thickets, can be used to enhance the profits of pharmaceutical companies while stalling innovation and placing undue financial burdens on the consumer.
Fil: Piñeiro, Federico Jesús. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Lanús. Rectorado. Instituto de Salud Colectiva; Argentina
Fil: Fernández Argüelles, Rogelio Alberto. Universidad Autónoma de Nayarit; México
description Introduction/Objective: To describe the chiral switch, an evergreening strategy used by AstraZeneca to position enantiopure esomeprazole as the new proton pump inhibitor market leader, displacing its predecessor omeprazole.Methodology: A four-stage systematic review which included: a preliminary review, bibliographic review using databases, classification of the body of literature, and content analysis.Results: Using different legal and commercial strategies, such as patent thickets and aggressive publicity campaigns, AstraZeneca transferred consumer loyalty from their successful omeprazole to esomeprazole, its new and more expensive patent protected product which has the same therapeutic value as its predecessor. This chiral switch allowed AstraZeneca to maintain monopoly prices, which increased the financial burden experienced by consumers and payors and may have also had a negative impact on access to the medication.Conclusions: This case study exemplifies how the current patent system, including patent thickets, can be used to enhance the profits of pharmaceutical companies while stalling innovation and placing undue financial burdens on the consumer.
publishDate 2022
dc.date.none.fl_str_mv 2022-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/200816
Piñeiro, Federico Jesús; Fernández Argüelles, Rogelio Alberto; A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy; Pro Pharma Communications International; Generics and Biosimilars Initiative Journal; 11; 2; 5-2022; 57-64
2033-6403
2033-6772
CONICET Digital
CONICET
url http://hdl.handle.net/11336/200816
identifier_str_mv Piñeiro, Federico Jesús; Fernández Argüelles, Rogelio Alberto; A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy; Pro Pharma Communications International; Generics and Biosimilars Initiative Journal; 11; 2; 5-2022; 57-64
2033-6403
2033-6772
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://gabi-journal.net/a-case-study-of-astrazenecas-omeprazole-esomeprazole-chiral-switch-strategy.html
info:eu-repo/semantics/altIdentifier/doi/10.5639/gabij.2022.1102.011
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Pro Pharma Communications International
publisher.none.fl_str_mv Pro Pharma Communications International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614415669788672
score 13.069144

Publicaciones similares